The Medicare GLP-1 Bridge is a short term demonstration program that allows eligible Medicare Part D beneficiaries to receive coverage of certain GLP-1 medications for weight management
Conclusion We explored the relationship between GLP-1 RAs and gastrointestinal AEs from various perspectives and quantified the potential risks based on a comprehensive and systematic retrospective analysis of the FAERS database
They found widespread associations with benefits to cognitive and behavioral health, while also revealing increased risks for pancreatitis and kidney conditions, among others
2 The medical triad Obesity, as well as DM, are conditions associated with a heightened risk of various cancers, including pancreatic, colorectal, breast, or liver cancer, and an increased mortality risk also accompanies them [8]
So it's really a way of doing a beautifully randomized controlled trial with an observational study because you're not biased